ストックスクリーナーアプリを入手
37.01
0.90%
0.33
アフターアワーズ：
37.01
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Can Agios Pharmaceuticals Inc. withstand a market correction2025 Sector Review & Consistent Growth Equity Picks - sundaytimes.kr
How to track smart money flows in Agios Pharmaceuticals Inc.Earnings Overview Report & Advanced Swing Trade Entry Plans - Newser
Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Performance Recap & Long-Term Safe Return Strategies - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyJuly 2025 Movers & AI Optimized Trade Strategies - Newser
Can Agios Pharmaceuticals Inc. generate free cash flowCEO Change & Weekly Sector Rotation Insights - thegnnews.com
Published on: 2025-08-13 06:00:50 - Newser
How institutional ownership impacts Agios Pharmaceuticals Inc. stockJuly 2025 Action & Weekly High Potential Alerts - Newser
Can Agios Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Entry and Exit Point Tips From Traders - 선데이타임즈
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire
Full technical analysis of Agios Pharmaceuticals Inc. stockLow Exposure Strategy with Sector Analysis - Newser
How Agios Pharmaceuticals Inc. stock performs during market volatilityMachine Learning Stock Price Forecast Tool - Newser
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios Pharmaceuticals Shares Plunge 23% Amid Safety Concerns - AInvest
TR | OpenAI4o Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $38 - 富途牛牛
Can a trend reversal in Agios Pharmaceuticals Inc. lead to recoveryChart Driven Entry Timing for Swing Trades - Newser
TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada
Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com
Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech
Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating - 富途牛牛
Envestnet Asset Management Inc. Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛
SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns - Asianet Newsable
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times
Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan
Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
Agios evaluating fourth Pyrukynd case after analyst report - TipRanks
Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com
Agios Pharmaceuticals Becomes Oversold (AGIO) - Nasdaq
Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest
Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha
Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada
How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News
Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News
What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News
What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News
What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News
What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest
Agios Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN
Why is Agios Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Forecasts From AI Tools - Jammu Links News
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $50 to $65 - 富途牛牛
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Agios 2025 Q2 Earnings Misses Targets as Net Income Declines 16.5% - AInvest
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals: Q2 Earnings Snapshot - Greenwich Time
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insight - GuruFocus
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):